Hypercoagulability as a contributor to thrombotic complications in the liver transplant recipient

Liver International

Volumn 33, Issue 6, 2013, Pages 820-827

  Arshad, Freeha ^a   Lisman, Ton ^a   Porte, Robert J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Coagulation; Hemostasis; Hypercoagulability; Orthotopic liver transplantation; Platelets; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 5 LEIDEN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE INTERMITTENT PORPHYRIA; ANTICOAGULANT THERAPY; ARTICLE; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; FAMILIAL AMYLOID POLYNEUROPATHY; GRAFT RECIPIENT; HEPARIN INDUCED THROMBOCYTOPENIA; HEPATIC ARTERY THROMBOSIS; HUMAN; HYPERCOAGULABILITY; KIDNEY FAILURE; LABORATORY TEST; LIVER GRAFT; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE RENAL FAILURE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM; THROMBOSIS PREVENTION;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; FIBRINOLYTIC AGENTS; HUMANS; LIVER TRANSPLANTATION; RISK ASSESSMENT; RISK FACTORS; THROMBOPHILIA; THROMBOSIS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 84878936507     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12140     Document Type: Article

References (64)

1. Lewis JH, Bontempo FA, Cornell F, et al. Blood use in liver transplantation. Transfusion 1987; 27: 222-5.
2. de Boer MT, Molenaar IQ, Hendriks HG, Slooff MJ, Porte RJ. Minimizing blood loss in liver transplantation: progress through research and evolution of techniques. Dig Surg 2005; 22: 265-75.
3. Tripodi A, Mannucci P. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365: 147-56.
4. Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 2010; 116: 878-85.
5. Duffy JP, Hong JC, Farmer DG, et al. Vascular complications of orthotopic liver transplantation: experience in more than 4200 patients. J Am Coll Surg 2009; 208: 896-905.
6. Sieders E, Peeters PM, TenVergert EM, et al. Early vascular complications after paediatric liver transplantation. Liver Transpl 2000; 6: 326-32.
7. Zhao J, Lu S, Yan L, et al. Incidence and treatment of hepatic artery complications after orthotopic liver transplantation. World J Gastroenterol 2003; 9: 2853-5.
8. Silva M, Jambulingam P, Gunson B, et al. Hepatic artery thrombosis following orthotopic liver transplantation: a 10-year experience from a single centre in the United Kingdom. Liver Transpl 2006; 12: 146-51.
9. Lerut J, Tzakis AG, Bron K, et al. Complications of venous reconstruction in human orthotopic liver transplantation. Ann Surg 1987; 205: 404-14.
10. Rodríguez Castro K, Porte R, Nadal E, et al. Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: a systematic review. Transplantation 2012, 94: 1145-53.
11. Yerdel MA, Gunson B, Mirza D, et al. Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation 2000; 69: 1873-81.
12. Gologorsky E, De Wolf AM, Scott V, et al. Intracardiac thrombus formation and pulmonary thromboembolism immediately after graft reperfusion in 7 patients undergoing liver transplantation. Liver Transpl 2001; 7: 783-9.
13. Warnaar N, Molenaar IQ, Colquhoun SD, et al. Intraoperative pulmonary embolism and intracardiac thrombosis complicating liver transplantation: a systematic review. J Thromb Haemost 2008; 6: 297-302.
14. Ishitani M, Angle J, Bickston S, et al. Liver transplantation: incidence and management of deep venous thrombosis and pulmonary emboli. Transplant Proc 1997; 29: 2861-3.
15. Borg MA, van der Wouden EJ, Sluiter WJ, et al. Vascular events after liver transplantation: a long-term follow-up study. Transpl Int 2008; 21: 74-80.
16. Pfitzmann R, Nssler N, Hippler Benscheidt M, Neuhaus R, Neuhaus P. Long-term results after liver transplantation. Transplant Int 2008; 21: 234-46.
17. Abbasoglu O, Levy MF, Brkic BB, et al. Ten years of liver transplantation: an evolving understanding of late graft loss. Transplantation 1997; 64: 1801-7.
18. Rabkin JM, de La Melena V, Orloff SL, et al. Late mortality after orthotopic liver transplantation. Am J Surg 2001; 181: 475-9.
19. Albeldawi M, Aggarwal A, Madhwal S, et al. Cumulative risk of cardiovascular events after orthotopic liver transplantation. Liver Transpl 2012; 18: 370-5.
20. Madhwal S, Atreja A, Albeldawdi M, et al. Is liver transplantation a risk factor for cardiovascular disease? Meta analysis of observational studies. Liver Transpl 2012; 18: 1140-11406.
21. Vanwagner L, Bhave M, Te H, et al. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology 2012; 56: 1741-50.
22. Roberts L, Patel R, Arya R. Haemostasis and thrombosis in liver disease. Br J Haematol 2010; 148: 507-21.
23. Lisman T, Porte RJ. The role of platelets in liver inflammation and regeneration. Semin Thromb Hemost 2010; 36: 170-4.
24. Ferro D, Angelico F, Caldwell S, Violi F. Bleeding and thrombosis in cirrhotic patients: what really matters? Digest Liver Dis 2012; 44: 275-9.
25. Witters P, Freson K, Verslype C, et al. Review article: blood platelet number and function in chronic liver disease and cirrhosis. Aliment Pharmacol Ther 2008; 27: 1017-29.
26. Escolar G, Cases A, Vias M, et al. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation. Haematologica 1999; 84: 614-9.
27. Lisman T, Adelmeijer J, de Groot PG, Janssen HLA, Leebeek FWG. No evidence for an intrinsic platelet defect in patients with liver cirrhosis-studies under flow conditions. J Thromb Haemost 2006; 4: 2070-2.
28. Lisman T, Bongers TN, Adelmeijer J, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53-61.
29. Pereboom IT, de Boer MT, Haagsma EB, et al. Platelet transfusion during liver transplantation is associated with increased post-operative mortality due to acute lung injury. Anesth Analg 2009; 108: 1083-91.
30. Pereboom IT, Adelmeijer J, van Leeuwen Y, et al. Development of a severe von Willebrand factor/ADAMTS13 dysbalance during orthotopic liver transplantation. Am J Transplant 2009; 9: 1189-96.
31. Claus R, Bockmeyer C, Budde U, et al. Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. Thromb Haemost 2009; 101: 239-47.
32. Andersson H, Siegerink B, Luken B, et al. High VWF, low ADAMTS13 and oral contraceptives increase the risk of ischaemic stroke and myocardial infarction in young women. Blood 2011; 119: 1555-60.
33. Pereboom IT, Adelmeijer J, van Leeuwen Y, et al. No evidence for systemic platelet activation during or after orthotopic liver transplantation. Liver Transpl 2009; 15: 956-62.
34. Pereboom IT, Lisman T, Porte RJ. Platelets in liver transplantation: friend or foe? Liver Transpl 2008; 14: 923-31.
35. Tripodi A, Salerno F, Chantarangkul V, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41: 553-8.
36. Tripodi A, Primignani M, Chantarangkul V, et al. An imbalance of pro- vs anticoagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009;137:2105-11.
37. Gatt A, Riddell A, Calvaruso V, et al. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost 2010; 8: 1994-2000.
38. Ben Ari Z, Panagou M, Patch D, et al. Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography. J Hepatol 1997;26:554-9.
39. Tripodi A, Primignani M, Chantarangkul V, et al. The coagulopathy of cirrhosis assessed by thrombo elastometry and its correlation with conventional coagulation parameters. Thromb Res 2009; 124: 132-6.
40. Lisman T, Bakhtiari K, Pereboom IT, et al. Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation tests. J Hepatol 2010; 52: 355-61.
41. Porte RJ, Bontempo FA, Knot EA, et al. Tissue-type-plasminogen-activator-associated fibrinolysis in orthotopic liver transplantation. Transplant Proc 1989; 21: 3542.
42. Lisman T, Leebeek FWG, Meijer K, et al. Recombinant factor VIIa improves clot formation, but not fibrolytic potential in patients with cirrhosis and during liver transplantation. Hepatology 2002; 35: 616-21.
43. Meltzer M, Doggen CJM, de Groot P, Rosendaal F, Lisman T. The impact of the fibrinolytic system on the risk of venous and arterial thrombosis. Semin Thromb Hemost 2009; 35: 468-77.
44. Dowman J, Gunson B, Mirza D, et al. LT-11-056 liver transplantation for acute intermittent porphyria is complicated by a high rate of hepatic artery thrombosis. Liver Transpl 2011; 18: 195-200.
45. Bispo M, Marcelino P, Freire A, et al. High incidence of thrombotic complications early after liver transplantation for familial amyloidotic polyneuropathy. Transplant Int 2009; 22: 165-71.
46. Pereboom IT, Adelmeijer J, van der Steege G, et al. Prothrombotic gene polymorphisms: possible contributors to hepatic artery thrombosis after orthotopic liver transplantation. Transplantation 2011; 92: 587-93.
47. Mas V, Fisher R, Maluf D, et al. Hepatic artery thrombosis after liver transplantation and genetic factors: prothrombin G20210A polymorphism. Transplantation 2003; 76: 247-9.
48. Madalosso C, de Souza NF, Ilstrup DM, Wiesner RH, Krom RA. Cytomegalovirus and its association with hepatic artery thrombosis after liver transplantation. Transplantation 1998; 66: 294-7.
49. Oh CK, Pelletier SJ, Sawyer RG, et al. Uni- and multi-variate analysis of risk factors for early and late hepatic artery thrombosis after liver transplantation. Transplantation 2001; 71: 767-72.
50. Gunsar F, Rolando N, Pastacaldi S, et al. Late hepatic artery thrombosis after orthotopic liver transplantation. Liver Transpl 2003; 9: 605-11.
51. Rahbar A, Soderberg-Naucler C. Human cytomegalovirus infection of endothelial cells triggers platelet adhesion and aggregation. J Virol 2005; 79: 2211-20.
52. Warner P, Fusai G, Glantzounis G, et al. Risk factors associated with early hepatic artery thrombosis after orthotopic liver transplantation - univariable and multivariable analysis. Transplant Int 2011; 24: 401-8.
53. Vivarelli M, Cucchetti A, La Barba G, et al. Ischaemic arterial complications after liver transplantation in the adult: multivariate analysis of risk factors. Arch Surg 2004; 139: 1069-74.
54. Vivarelli M, La Barba G, Cucchetti A, et al. Can antiplatelet prophylaxis reduce the incidence of hepatic artery thrombosis after liver transplantation? Liver Transpl 2007; 13: 651-4.
55. Bianchi G, Marchesini G, Marzocchi R, Pinna A, Zoli M. Metabolic syndrome in liver transplantation: relation to aetiology and immunosuppression. Liver Transpl 2008; 14: 1648-54.
56. Laryea M, Watt K, Molinari M, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007; 13: 1109-14.
57. Dielis AWJH, Smid M, Spronk HMH, et al. The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems. Hypertension 2005; 46: 1236-42.
58. Alessi M, Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thromb Haemost 2008; 99: 995-1000.
59. Senzolo M, Sartori M, Rodriguez Castro K, Simioni P, Rossetto V. Increased thrombin generation in liver transplant recipients: does immunosuppressive therapy play a role? Liver Transpl 2011;17:347-8.
60. Huang LQ, Whitworth JA, Chesterman CN. Effects of cyclosporin A and dexamethasone on haemostatic and vasoactive functions of vascular endothelial cells. Blood Coagul Fibrinolysis 1995; 6: 438-45.
61. Bombeli T, Mller M, Straub PW, Haeberli A. Cyclosporine-induced detachment of vascular endothelial cells initiates the intrinsic coagulation system in plasma and whole blood. J Lab Clin Med 1996; 127: 621-34.
62. Senzolo M, Rodriguez Castro KI, Rossetto V, et al. Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis. J Thromb Haemost 2012;10:1823-9.
63. Lisman T, Porte R. Towards a rational use of low-molecular-weight heparin in patients with cirrhosis. Liver Int 2011; 31: 1063-1063.
64. Villa E, Cammà C, Marietta M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143: 1253-60.